Skip to main content
Erschienen in: Clinical and Experimental Medicine 7/2023

08.04.2023 | Research

Epidemiology and prognostic factors of 114 patients with mycosis fungoides in a Moroccan cohort: a 29-year review

verfasst von: Hicham Titou, Ahmed Bouhamidi

Erschienen in: Clinical and Experimental Medicine | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Limited data regarding survival of Moroccan patients with mycosis fungoides (MF). To evaluate the clinical profile and long-term outcomes of these patients. A retrospective review of 114 MF cases diagnosed from 1993 to 2022 who were followed up for more than 6 months of diagnosis was performed. Of 114 patients, 71.9% were male and the median age at diagnosis was 56 years. Approximately 64 and 36% of the patients had an early stage and advanced stage, respectively. Median follow-up duration was 56 months, and median duration of symptoms before diagnosis was 31 months. Various subtypes were observed, including mycosis fungoides folliculotropic (12.3%), poikilodermatous (11.4%), and palmaris et plantaris MF (5.3%). The 10-year overall survival was 89% in early-stage patients and 48.8% in advanced-stage patients. Complete response to treatment occurred in 45.6%, stable disease in 16.7% and disease progression in 7.9% of patients. Older age of > 60 years, higher T-stage (T3/T4) and advanced-stage MF were statistically significant in predicting poorer outcomes in MF. Despite delay in diagnosis, most cases of MF in Morocco were diagnosed in early stages. We observed a high proportion of classic MF and favorable prognosis.
Literatur
1.
Zurück zum Zitat Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73.CrossRefPubMedPubMedCentral Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.CrossRefPubMed Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.CrossRefPubMed
3.
Zurück zum Zitat Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–66.CrossRefPubMed Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–66.CrossRefPubMed
4.
Zurück zum Zitat Sun G, Berthelot C, Li Y, et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol. 2009;60(2):231–5.CrossRefPubMed Sun G, Berthelot C, Li Y, et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol. 2009;60(2):231–5.CrossRefPubMed
5.
Zurück zum Zitat Desai M, Liu S, Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sezary syndrome in the southeastern United States: a single institution cohort. J Am Acad Dermatol. 2015;72(2):276–85.CrossRefPubMed Desai M, Liu S, Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sezary syndrome in the southeastern United States: a single institution cohort. J Am Acad Dermatol. 2015;72(2):276–85.CrossRefPubMed
6.
Zurück zum Zitat Nashan D, Faulhaber D, Ständer S, Luger TA, Stadler R. Mycosis fungoides: a dermatological masquerader. Br J Dermatol. 2007;156(1):1–10.CrossRefPubMed Nashan D, Faulhaber D, Ständer S, Luger TA, Stadler R. Mycosis fungoides: a dermatological masquerader. Br J Dermatol. 2007;156(1):1–10.CrossRefPubMed
7.
Zurück zum Zitat Martínez-Escala ME, González BR, Guitart J. Mycosis fungoides variants. Surg Pathol Clin. 2014;7(2):169–89.CrossRefPubMed Martínez-Escala ME, González BR, Guitart J. Mycosis fungoides variants. Surg Pathol Clin. 2014;7(2):169–89.CrossRefPubMed
8.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissue. Revised 4th edition. Lyon : IARC Press, 2017. Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissue. Revised 4th edition. Lyon : IARC Press, 2017.
9.
Zurück zum Zitat Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53:1053–63.CrossRefPubMed Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53:1053–63.CrossRefPubMed
10.
Zurück zum Zitat Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051–60.CrossRefPubMed Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051–60.CrossRefPubMed
13.
Zurück zum Zitat Geller S, Lebowitz E, Pulitzer MP, Horwitz SM, Moskowitz AJ, Dusza S, Myskowski PL. Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center. J Am Acad Dermatol. 2020; 83(2):430–439. https://doi.org/10.1016/j.jaad.2019.08.073. Epub 2019 Sep 6. PMID: 31499157; PMCID: PMC7058509. Geller S, Lebowitz E, Pulitzer MP, Horwitz SM, Moskowitz AJ, Dusza S, Myskowski PL. Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center. J Am Acad Dermatol. 2020; 83(2):430–439. https://​doi.​org/​10.​1016/​j.​jaad.​2019.​08.​073. Epub 2019 Sep 6. PMID: 31499157; PMCID: PMC7058509.
14.
Zurück zum Zitat Mourad A, Gniadecki R. Overall survival in mycosis fungoides: a systematic review and meta-analysis. J Invest Dermatol. 2020;140(495–497): e5. Mourad A, Gniadecki R. Overall survival in mycosis fungoides: a systematic review and meta-analysis. J Invest Dermatol. 2020;140(495–497): e5.
15.
Zurück zum Zitat Amorim GM, Niemeyer-Corbellini JP, Quintella DC, et al. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An Bras Dermatol. 2018;93:546–52.CrossRefPubMedPubMedCentral Amorim GM, Niemeyer-Corbellini JP, Quintella DC, et al. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An Bras Dermatol. 2018;93:546–52.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Horesh N, Horowitz NA. Does gender matter in non-Hodgkin lymphoma? differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J. 2014;5(4):e0038.CrossRefPubMedPubMedCentral Horesh N, Horowitz NA. Does gender matter in non-Hodgkin lymphoma? differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J. 2014;5(4):e0038.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Lebowitz E, Geller S, Flores E, et al. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of 174 patients. J Eur Acad Dermatol Venereol. 2019;33:108–14.CrossRefPubMed Lebowitz E, Geller S, Flores E, et al. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of 174 patients. J Eur Acad Dermatol Venereol. 2019;33:108–14.CrossRefPubMed
19.
Zurück zum Zitat Quaglino P, Pimpinelli N, Berti E, et al. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian group of cutaneous lymphomas. Cancer. 2012;118:5830–9.CrossRefPubMed Quaglino P, Pimpinelli N, Berti E, et al. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian group of cutaneous lymphomas. Cancer. 2012;118:5830–9.CrossRefPubMed
21.
Zurück zum Zitat Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. Am Acad Dermatol. 2002;2002(47):914–8.CrossRef Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. Am Acad Dermatol. 2002;2002(47):914–8.CrossRef
22.
Zurück zum Zitat Smoller BR, Santucci M, Wood GS, et al. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2003;17:1277–311.CrossRefPubMed Smoller BR, Santucci M, Wood GS, et al. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2003;17:1277–311.CrossRefPubMed
24.
Zurück zum Zitat Dereure O, Levi E, Kadin ME. T-cell clonality in pityriasis lichenoides et varioliformis acuta: a heteroduplex analysis of 20 cases. Arch Dermatol. 2000;136:1483–6.CrossRefPubMed Dereure O, Levi E, Kadin ME. T-cell clonality in pityriasis lichenoides et varioliformis acuta: a heteroduplex analysis of 20 cases. Arch Dermatol. 2000;136:1483–6.CrossRefPubMed
25.
Zurück zum Zitat Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer. 2006;42(8):1014–30.CrossRefPubMed Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer. 2006;42(8):1014–30.CrossRefPubMed
26.
Zurück zum Zitat Korekawa A, Kaneko T, Nakajima K, et al. Mycosis fungoides bullosa associated with bullous pemphigoid. Int J Dermatol. 2015;54(9):e366–8.CrossRefPubMed Korekawa A, Kaneko T, Nakajima K, et al. Mycosis fungoides bullosa associated with bullous pemphigoid. Int J Dermatol. 2015;54(9):e366–8.CrossRefPubMed
27.
Zurück zum Zitat Roenigk HH Jr, Castrovinci AJ. Mycosis fungoides bullosa. Arch Dermatol. 1971;104(4):402–6.CrossRefPubMed Roenigk HH Jr, Castrovinci AJ. Mycosis fungoides bullosa. Arch Dermatol. 1971;104(4):402–6.CrossRefPubMed
28.
Zurück zum Zitat Lee JS, Yun SJ, Lee JB, et al. A case of hyperpigmented mycosis fungoides: a rare variant. J Eur Acad Dermatol Venereol. 2007;21:983.CrossRefPubMed Lee JS, Yun SJ, Lee JB, et al. A case of hyperpigmented mycosis fungoides: a rare variant. J Eur Acad Dermatol Venereol. 2007;21:983.CrossRefPubMed
29.
Zurück zum Zitat Pavlovsky L, Mimouni D, Amitay-Laish I, Feinmesser M, David M, Hodak E. Hyperpigmented mycosis fungoides: an unusual variant of cutaneous T-cell lymphoma with a frequent CD8+ phenotype. J Am Acad Dermatol. 2012;67:69.CrossRefPubMed Pavlovsky L, Mimouni D, Amitay-Laish I, Feinmesser M, David M, Hodak E. Hyperpigmented mycosis fungoides: an unusual variant of cutaneous T-cell lymphoma with a frequent CD8+ phenotype. J Am Acad Dermatol. 2012;67:69.CrossRefPubMed
30.
Zurück zum Zitat Suzuki SY, Ito K, Ito M, Kawai K. Prognosis of 100 Japanese patients with mycosis fungoides and Sezary syndrome. J Dermatol Sci. 2010;57:37–43.CrossRefPubMed Suzuki SY, Ito K, Ito M, Kawai K. Prognosis of 100 Japanese patients with mycosis fungoides and Sezary syndrome. J Dermatol Sci. 2010;57:37–43.CrossRefPubMed
31.
Zurück zum Zitat Tobisawa S, Honma M, Ishida-Yamamoto A, Sajio Y, Iizuka H. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sezary syndrome: clusterin expression as a novel prognostic factor. J Dermatol Sci. 2013;71:160–6.CrossRefPubMed Tobisawa S, Honma M, Ishida-Yamamoto A, Sajio Y, Iizuka H. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sezary syndrome: clusterin expression as a novel prognostic factor. J Dermatol Sci. 2013;71:160–6.CrossRefPubMed
32.
Zurück zum Zitat Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised international society for cutaneous lymphomas/European organisation for research and treatment of cancer staging proposal. J Clin Oncol. 2010;28:4730–9.CrossRefPubMed Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised international society for cutaneous lymphomas/European organisation for research and treatment of cancer staging proposal. J Clin Oncol. 2010;28:4730–9.CrossRefPubMed
Metadaten
Titel
Epidemiology and prognostic factors of 114 patients with mycosis fungoides in a Moroccan cohort: a 29-year review
verfasst von
Hicham Titou
Ahmed Bouhamidi
Publikationsdatum
08.04.2023
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 7/2023
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-023-01056-7

Weitere Artikel der Ausgabe 7/2023

Clinical and Experimental Medicine 7/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.